Primary brain tumors are a heterogeneous group of malignant and benign brain parenchymal tumors and the structures around them. Tanzania is ranked as a low human development index (HDI) country in the UN Development Program’s four-level system. There were 330,000 cases of CNS cancer and 227,000 deaths worldwide in 2016, with an increase in age-standardized incidence rates of CNS cancer from 17.3% to 26.9% globally between 1990 and 2016. The top three countries with the highest number of incident cases were China, the USA, and India [1]. These tumors can be classified as grades 1 to 4 (WHO), while grades 1 and 2 are defined as benign tumors, while grades 3 and 4 are defined as malignant tumors [2]. According to Globocan 2018 estimates, the worldwide incidence of age-standardized rates (ASR) of the brain and nervous system cancer in high/very-high HDI (Human Development Index) regions versus low/medium HDI regions was 5.0 and 2.4 for men and 4.0 and 1.7 for women respectively. These incidence rates were about twice as high in high/very high HDI countries as in low/average HDI countries and slightly higher for men than for women [3].

In Tanzania, primary brain tumors are rare, accounting for around 3% of all cancer cases per year (hospital data). They are associated with significant morbidity and mortality due to the disease itself and treatment modalities, placing a greater burden on patients and caregivers [4]. Neuroepithelial tissue tumors are the most common primary intra-axial brain tumors. Gliomas are the most common and are further subdivided into oligodendrogliomas, astrocytomas, ependymomas, and mixed oligoastrocytomas [5].

The treatment of brain cancer is multidisciplinary and patients navigate between the neurosurgeon, radiologist, and oncologist [6]. Ocean Road Cancer Institute (ORCI) specializes in radiotherapy and chemotherapy for cancer patients while surgery is carried out in other centers. There is a paucity of data concerning clinic-pathological profiles of the patients with primary brain tumors in Tanzania and the treatment modalities used. The purpose of the study was to establish a baseline profile of patients with primary brain tumors in Tanzania.

The study recruited 61 patients.

The most commonly affected age group was 15 - 39 years. The mean and median age of the respondents was 42.4 years and 41.4 respectively, with a range of 15 - 73 years. The ratio of females to males was 1:1.2. The mean age of the females was 41.8 years and the mean age of males was 42.9 years, although the difference was not statistically significant by t-test (P = 0.08) (Table 1).

The most common histology was Glioblastoma (GBM) (37.7%) and most respondents had a high-grade tumor (66%). About two-thirds of the respondents presented with headaches. The most commonly affected lobe was the frontal lobe (29.5%). About 91.8% of all tumors were supratentorial and 8.2% were infratentorial (Table 2).

GBM was the most common tumor (39.3%) (Figure 1).

Headache was the most common symptom, followed by motor weakness in all affected lobes (Figure 2).

ECOG—Eastern Cooperative Oncology Group.

In this series, most of the respondents had subtotal-tumor excision (STR) (55.7%). Respondents with Ependymoma had the highest gross tumor resection (GTR) rate (25%) followed by Astrocytoma (35%). The GTR rate for GBM was about 26%. About 80% of the respondents were given radiotherapy, and for about two-thirds of the respondents who were given adjuvant radiotherapy the

technique used was 3DCRT. The mean overall EQD2 was 45.8 Gy. About 28.6% of the respondents who were given adjuvant radiotherapy were also given concurrent chemo-radiotherapy and the most common cytotoxic drug used was Temozolamide (87.5%). About 60% of the patients with GBM were given concurrent temozolomide (Table 3).

Respondents with GBM had the highest mean age, and respondents with germinoma had the lowest mean age. Meningioma was more common in females (M:F = 1:2.7). Respondents with meningioma and medulloblastoma were treated with the overall highest mean EQD2 (53 Gy) and respondents with germinoma were treated with the overall lowest mean EQD2 (30 Gy). Among the respondents who were treated with 3DCRT, those who had meningioma were treated with the highest EQD2 (55.9 Gy) (Table 4).

About 82% of the patients had reports of histologic grades. Two-thirds of the tumors had high-grade histology. All GBM and Oligodendroglioma were of high grade. Tumors that had the highest proportions of low-grade histology were astrocytoma (75%), meningioma (71.4%), and brainstem glioma (66.7%) (Table 5).

Patients with high-grade intracranial tumors were treated with a lower dose (EQD2) in comparison to those with high-grade tumors and the difference was statistically significant by t-test (Table 6).

The 3-year OS rate was 18% and the median survival time was 24 months.

The overall mean age in this study at diagnosis was 42.4 years and the age range was between 15 and 73 years, which is similar to a study by Lapointe et al. [7] but differs from a study done in Ghana by Ekpene et al. [8] showed a small mean age of 32 years (range 2 - 73 years) in patients with primary brain tumors. The higher mean age in our study could be because of the exclusion of pediatric patients.

The female to male ratio was 1:1.2 in the index study. It’s consistent with an

2DRT—Two-dimensional radiotherapy; 3DCRT—Three-dimensional conformal radiotherapy.

ST—Supratentorial; IT—Infratentorial; GBM—Glioblastoma; EQD2—Equivalent dose in 2 Gy fractions.

GBM—Glioblastoma.

P = 0.02.

Ekpene et al. study in Ghana [8]. In this study, meningioma was more common in females with M:F ratio of 1:2.7. Other studies have also shown a higher preponderance of women developing meningioma and they linked this preponderance with reproductive and hormonal factors, which predisposes women to be more at risk compared to males [8].

Most of the tumors were of high grade (66.7%) and the most common histology was glioblastoma (GBM) accounting for 39.3%. Similar findings were observed in England by Wanis et al. [9]. Some other studies reported meningioma to be the most common primary brain tumor, which is not in keeping with findings from the index study, possibly because of ethnic, geographical, and environmental differences [10]. The finding that most of the tumors were of high grade could be attributed to the type of patients that are referred to ORCI. ORCI is a tertiary hospital specializing in providing radiotherapy and chemotherapy as adjuvant treatment, while surgery is done in other centers. Patients with high-grade tumors and subtotal resection (STR) are usually referred for adjuvant treatment. That being said, Wanis et al. also found that the majority (two-thirds) of primary brain tumors in England are malignant (high grade) by using a population-based cancer registry [9].

The most affected site was the frontal lobe. This is consistent with other studies that have also shown frontal lobe dominance, especially in malignant tumors [11]. The most common symptoms were headaches (64.8%), weakness (34%), vision impairment (26.6%), and seizures (17%). Weakness and blindness could be because of the direct effect of tumor or post-surgery sequelae [6]. The headache was also the most common symptom in other studies [11] although other studies showed seizures as the most common presenting symptom [12]. Seizures have been reported to be more frequent in low-grade gliomas and GBM, developing from low-grade astrocytomas as compared to “primary” GBM. A lower incidence of epilepsy in high-grade gliomas may be because of their preferentially white matter location and the incessant tumoral growth that might prevent the development of the “epileptogenic focus”. We might relate a low frequency of epilepsy in these patients to shorter survival from high-grade tumors compared with low-grade tumors [13]. However, in this study, there was no statistically significant association between grade and the occurrence of seizures, perhaps because of the inclusion of meningiomas.

Treatment decisions are based on tumor type, tumor site, malignant potential, the patient’s age, and physical condition. Treatment may require only surveillance, but commonly includes surgery, radiotherapy, chemotherapy, or a combination. The preferred treatment of primary brain tumors is the maximal safe surgical removal of the tumor, followed by radiotherapy and chemotherapy. Benefits of maximal resection include relief of mass effect, decreased tumor burden, improved diagnosis, and a trend toward prolonged survival [14].

In this series, the overall gross tumor resection (GTR) rate for all intracranial tumors was 26.2%, but it ranged from 0% in oligodendrogliomas to 50% in ependymomas. The GTR rate for GBM was 26.1%. In a retrospective study done in Turkey to assess the extent of resection among gliomas, they showed GTR rate was 62.2% [15]. This difference could be because of a difference in the definition of the extent of surgery and variation in resource availability. In the index of study, the extent of resection was determined by using the surgical notes after resection and not the post-operative brain MRI. Post-operative brain MRI is a gold standard in assessing the extent of tumor resection [6]. It will be very interesting to find out how the survival of patients with intracranial tumors at ORCI compares to that in other parts of the world with such low GTR rates.

Radiotherapy can be used as primary treatment or adjuvant treatment following surgical resection. Radiotherapy can improve progression-free survival and overall survival in patients with high-risk low-grade gliomas, defined as patients younger than 40 years with subtotal resection or biopsy, or patients older than 40 years with any type of resection [14]. A total dose of 60 Gy in 30 fractions is usually delivered for GBM, and a dose of 59.4 Gy in 33 fractions is typically given for anaplastic gliomas [16]. A systemic analysis done by Kaur et al. Showed that doses below 50 Gy are inadequate for treating atypical meningioma and grade three meningioma [17]. In this study, the mean dose in 2 Gy fractions (EQD2) used to treat high-grade intracranial tumors was only 44.5 Gy, while that for low-grade intracranial tumors was 47.3 Gy. Doses of radiation therapy were low, possibly due to advanced disease at the time of presentation, unavailability of 3DCRT in the years before 2018, and poor patient performance status.

Temozolomide was administered to only two-thirds of patients with GBM who also received adjuvant radiotherapy following surgery, possibly as a result of affordability issues. Concurrent use of temozolomide and radiotherapy in high-grade glioma has been associated with improved survival and better outcomes compared to radiotherapy alone as was shown in a study by Stupp et al. which showed temozolomide improved median survival in newly diagnosed GBM when given concurrently with radiotherapy and for maintenance after radiotherapy [18].

In conclusion, this is the first single institutional study from Tanzania to elaborate on clinical-pathological features and treatment modalities of patients with primary brain tumors. GBM was the most common tumor among adults. The GTR rate was low and radiotherapy doses were low. Few patients were able to afford temozolomide. The limitations of this research include histological classification without molecular profiling. In addition, the study was subject to reference bias since ORCI is the reference cancer center, which provides mainly radiotherapy and chemotherapy without surgical facilities. Consequently, these outcomes may not be generalized to centers with surgical facilities. We couldn’t gather some information because of the retrospective nature of the study. A population-specific cancer registry is essential for obtaining the exact incidence of primary brain tumors in Tanzania.

Permission to carry out the study was sought from Ocean Road Cancer Institute Ethics Committee with reference number 10/VOL.XXI/16B. All methods were performed according to ORCI guidelines and regulations.

The datasets used and/or analyzed during the current study are available from the corresponding author on request.

We would not have been able to complete this study without the contributions of the Clinical Oncology, Department of ORCI, and staff of the ORCI cancer registry department, particularly Mr. Jaffari Omary.

Concept and design: Alita S. Mrema, Emmanuel Lugina, Salama Iddy;

Collection and assembly of data: Salama Iddy, Alita S. Mrema, Emmanuel Lugina;

Data analysis and interpretation: Emmanuel L. Lugina, Alita S. Mrema;

Financial support: Alita S. Mrema, Emmanuel Lugina;

Manuscript writing: Emmanuel L. Lugina, Alita Mrema;

Final approval of manuscript: Alita S. Mrema, Salama Iddy, Emmanuel L. Lugina;

Agree to be accountable for all aspects of work: Alita S. Mrema, Salama, Mamsau Ngoma, Nanzoke Mvungi, and Emmanuel L. Lugina.

The authors do not disclose any conflict of interest.

Mrema, A., Iddy, S., Ngoma, M., Mvungi, N. and Lugina, E. (2022) Clinical-Pathological Features and Treatment Modalities of Primary Brain Tumors in Tanzania—4 Years of Institutional Experience. Journal of Cancer Therapy, 13, 252-265. https://doi.org/10.4236/jct.2022.135021

The questionnaire

1) Hospital registration number …………….

2) Age (Years) ………..

3) Gender

a) Female

b) Male

4) Presenting symptoms (Circle all that apply)

a) Headache

b) Dizziness

c) Weakness

d) Seizures

e) Blindness

f) Loss of balance

g) Amnesia

h) Loss of consciousness

i) Incontinence

5) What lobe of affected?

a) Parietal

b) Frontal

c) Temporal

d) Occipital

6) Histology ………………….

7) Grade ……………………..

a) Low grade

b) High Grade

8) Year of diagnosis …………..

9) Type of surgery

a) Gross tumor resection

b) Subtotal tumor resection

10) Was adjuvant radiotherapy given?

a) Yes

b) No

11) Type of radiotherapy

a) 2D radiotherapy

b) Conformal radiotherapy

12) Dose of radiotherapy in 2Gy fractions …………

13) Was concurrent chemotherapy given?

a) Yes

b) No

14) Type of chemotherapy given ……………………

15) Date at last contact

16) Status at last contact

a) Alive

b) Dead

c) Loss to follow up

GBM: Glioblastoma multiforme; EQD2: Equivalent dose in 2Gy fractions; ASR: Age-standardized rate; HDI: Human development Index; CNS: Central nervous system; GTR: Gross tumor resection; STR: Subtotal tumor resection.